Mexico’s Cofepris granted the world’s first sanitary registration for an RNA-based biofungicide on Aug. 12, 2026, handing a powerful green light to a new crop-protection tool while GreenLight Biosciences tied the approval to a Mexico City plant investment of close to US$100 million. The product is registered against powdery mildew in grapes, caused by Erysiphe necator. A separate GreenLight RNA acaricide for spider mites, covering crops such as avocado and strawberry, is still under Cofepris evaluation.
Who Gets to Decide
Cofepris did the approving, with the move coming in coordination with Senasica and Semarnat. That’s the machinery at work: regulators, agencies, and corporate plans moving in lockstep while growers wait for permission slips from above. The company said the RNA acaricide is still under review, and no efficacy figure was disclosed for that product. The gate stays closed until the apparatus says otherwise.
The RNA biofungicide works by silencing a gene the fungus needs to survive, and Mexican regulators described the mechanism as one that “turns off the fungus’s gene” needed for survival. Officials said the RNA acts only on the target fungus and degrades naturally in soil, water and fruit. Those are the claims attached to the approval, the language of safety and precision that now travels with the product into the market.
What the Company Wants
GreenLight Biosciences founder and CEO Andrey Zarur announced the manufacturing plans alongside the approval. The specific commercial product name was not confirmed in available reporting. The company’s pitch is plain enough: a regulatory win, a factory, and a foothold in a region where agriculture is already organized around export demands and corporate supply chains.
The report said the approval was described as a shift in how regulators and growers think about crop protection and as a signal that Mexico is open to biotech innovation in agriculture if the science holds up. It was also framed as a precedent that could encourage other companies to bring similar products to the region and pressure other Latin American regulators to develop RNA-based crop-protection frameworks rather than waiting for approvals elsewhere. Argentina, Brazil and Chile all have large, export-driven farm sectors and could face pressure to fast-track similar approvals if the technology proves itself in Mexican fields.
That’s the real choreography here. One regulator opens the door, and the rest of the region gets nudged toward the same model, with export agriculture and biotech firms setting the pace.
Who Pays the Price
The article said conventional chemical fungicides are broad-spectrum tools that can harm beneficial fungi, disrupt soil ecosystems and leave residues that regulators and consumers increasingly frown upon. The RNA biofungicide, by contrast, is presented as a way for growers to maintain high yields while lowering environmental impact. Local production in Mexico City could support local supply chains, local jobs and a shorter distance between production and application for growers across North and Central America.
That’s the promise being sold: cleaner inputs, steadier yields, and a factory job or two wrapped around a larger system that still runs on export pressure and top-down control. The people working the fields don’t get to write the rules. The regulators do. The companies do. The growers get the product once the paperwork clears.
The article also said the U.S. EPA registered the first sprayable RNA pesticide in 2023. Now Mexico has gone first on a sanitary registration for an RNA-based biofungicide, and the region’s agricultural bosses will be watching closely to see how fast the rest of the bureaucratic chain can be made to move.